CBP-1008 

CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma)^[1][2][3].

CBP-1008 在 TRPV6 存在时比 TRPV6 不存在时显示出更快的 FRα 介导的内化和细胞毒性^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CBP-1008 在肿瘤中保留和积累，半衰期超过 48 h^[3]。
CBP-1008 的 MTD 在小鼠中达到 4 mg/kg，在大鼠中达到 2 mg/kg，在猴子中达到 1 mg/kg^[3]。
CBP-1008 对 FRα 和 TRPV6 阳性卵巢 PDX 肿瘤的疗效优于对至少一种标记物阴性卵巢 PDX 肿瘤的疗效，而且对 FRα⁺/TRPV6⁺ 肿瘤的生长抑制与 IHC 评分密切相关^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fu, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta pharmaceutica Sinica. B. 2023, 13(2), 498–516.  [Content Brief]

  [2]. Gong, et al. First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors. Journal of Clinical Oncology. 2023, 41 (16).

  [3]. Tan, et al. CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2022. 2022, 82(12_Suppl).